Tirzepatide
- Dual GIP / GLP-1 action
- Studied for significant fat loss and waistline reduction
- Improves blood-sugar control and insulin sensitivity markers
- Slower gastric emptying — longer, steadier fullness between meals
- Janoshik verified · Purity ≥ 99%
- 1× Tirzepatide
- 1× 3mL Bacteriostatic Water
- 5× 31G Insulin Syringes
- 5 Alcohol Prep Pads
- Certificate of Analysis
- Mixing Guide
Orders ship within 1–2 business days.
Free shipping on orders over ₱6,000.
30-day purity guarantee for independently lab-verified eligible claims.
Purity, identity, and quality verified by Janoshik Analytical.
Customer support on WhatsApp:
+63 947 174 7187
What researchers ask before ordering.
Tirzepatide is a 39-amino-acid dual receptor agonist: it engages both the GIP receptor and the GLP-1 receptor from one molecule. Single-target compounds such as semaglutide act on the GLP-1 receptor only. In the head-to-head SURPASS-2 trial published in the New England Journal of Medicine, the dual-agonist design is what the researchers set out to isolate, which is why tirzepatide has become the reference compound in comparative incretin research.
Related research
A guide to the dual GIP and GLP-1 receptor agonist, its development, and defining evidence.
Read researchGIP and GLP-1 explained, from receptor agonism to measured human-study outcomes.
Read researchA receptor-by-receptor comparison and guide to what current evidence does and does not support.
Read research
